Modelling of the Pharmacokinetics and Pharmacodynamics of the Low-DoseMethotrexate Treatment of Psoriasis with the Aim of Dosage Individualization

Czech version

Authors: J. Grim ¹; J. Chládek ¹; M. Šimková ²; J. Vaněčková ²; V. Koudelková ²; J. Martinková ¹; M. Nožičková ²
Authors‘ workplace: Ústav farmakologie Lékařské fakulty v Hradci Králové, Univerzita Karlova v Praze přednostka prof. MUDr. Jiřina Martínková, CSc. 2Klinika nemocí kožních a pohlavních, Fakultní nemocnice, Hradec Králové přednostka doc. MUDr. Marie Nožičková, CSc. ¹
Published in: Čes-slov Derm, , 2002, No. 4, p. 154-162
Category:

Overview

The intent of a prospective 3-month study was to evaluate the pharmacokinetics (PK) andpharmacodynamics (PD) of low-dose methotrexate (LDMTX) in recalcitrant psoriasis en plaques. 15males and 9 females (age 31-73 years) were assigned to 2 regimens of either 2.5-2.5-2.5 mg or 5-5-5 mg oral methotrexate (MTX), given in two 12-h intervals a week. HPLC was used to analysis of MTXconcentrations in plasma and urine. The comparison of MTX minimum plasma concentrationsrevealed that the steady state is reached after a third subdose (p

Key words:
low-dose methotrexate - psoriasis - PASI score

Full text is not available online.

If interested in a scan of this journal, contact NTO ČLS JEP.

Labels

Dermatology & STDs Paediatric dermatology & STDs

Dendritic Antigen Presenting Cells in the Pathogenesis of Psoriasis

Relapsing Erysipelas - Initial Experience with Oral Vaccination Treatment

Cultured Epidermal Keratinocytes in the Treatment of Leg Ulcers - Part I

Granulomatosis Orofacialis in Two Monozygotic Twins

Late Metastazing of a Malignant Melanoma

Haemangiomas in Children

Article was published in

Czech-Slovak Dermatology

2002 Issue 4